您的位置: 首页 > 农业专利 > 详情页

Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
专利权人:
SignPath Pharma Inc.
发明人:
Lawrence Helson
申请号:
US14268376
公开号:
US09682041B2
申请日:
2014.05.02
申请国别(地区):
US
年份:
2017
代理人:
摘要:
Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/
相关发明人
相关专利

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充